Cryo-Fluorescence Niche EMIT Imaging specializes in Cryo-Fluorescence Tomography (CFT) and offers fee-for-service research, presenting a strong opportunity to upsell advanced imaging services to biotech firms pursuing preclinical drug distribution and biodistribution studies.

Preclinical Imaging Platform The Xerra cryo-imaging system is available as instrumentation through EMIT, enabling potential cross-sell of in-house imaging capabilities to CROs, universities, and biotech startups needing high-resolution whole-body and tissue imaging.

Global Research Reach With international interest in CFT and a global scientific community, there is a path to partner on sponsored research, contract research, and milestone-based programs targeting drug delivery, protein expression, and co-localization studies.

Financials & Growth Current revenue range and ongoing funding indicate a scalable business model with room to expand service offerings, seek larger collaborations, and present as a cost-effective high-value imaging partner for late-stage preclinical programs.

Strategic Partnerships EMIT’s capabilities in whole-body drug distribution, target co-localization, and vascular/therapeutic protein tracking position it well to form alliances with pharmaceutical and biotech companies seeking advanced analytics for candidate screening and mechanism-of-action validation.